Table 1.
Group | Final body weighta,b (g) |
Tumor multiplicitya |
Inhibition | Tumor loada (mm3) |
Inhibition | Percentage of tumors (<0.5 mm) |
---|---|---|---|---|---|---|
Solvent Control | 22.3 ± 1.2 | 5.00 ± 2.00 | — | 0.30 ± 0.22 | — | 28.3 |
Budesonide | 20.0 ± 2.1 | 2.17 ± 1.64 | 56.7%* | 0.07 ± 0.06 | 78.4%* | 42.3 |
Gavage control | 20.9 ± 1.9 | 4.33 ± 1.63 | — | 0.36 ± 0.33 | — | 23.1 |
Pioglitazone | 23.0 ± 2.5 | 4.08 ± 2.11 | 5.8% | 0.13 ± 0.10 | 63.3%* | 50.8 |
Solvent and Gavage control | 20.1 ± 2.5 | 4.70 ± 2.41 | — | 0.26 ± 0.24 | — | 39.2 |
Budesonide and pioglitazone | 19.2 ± 1.7 | 2.09 ± 1.45 | 55.5%*,† | 0.03 ± 0.02 | 89.6%*,† | 87.0 |
Data shown as mean ± SD.
Average body weight after 20 wk treatment (22 wk after B(a)P injection).
P < 0.05 versus control.
P < 0.01 versus pioglitazone group.